Australia: A highly attractive environment for drug development

Australia offers a highly favorable environment for drug research and development, with a mature infrastructure and experienced, capable local resources and expertise. Considering global geopolitical uncertainties, Australia presents a compelling option for sponsors to consider. This first article in a three-part series illustrates the Australian economy, demographics, healthcare investments and expenditures, and the growth of the pharmaceutical market and clinical trials. Ensuing articles will explore the landscape for clinical trials, including the therapeutic areas, the strength of patient centricity and innovation adoption, and the regulatory and reimbursement environment.

Interested in more? Check out part 2 and part 3.

Open PDF

Return to Insights Center

Related Insights


Can Chinese Phase I data from the West accelerate China drug development?

Mar 17, 2021


A hybrid model supports globally diverse site participation for a retrospective cancer study

Jul 24, 2023


Six steps to maximize inclusivity within medical communications | Part 1: Race and Ethnicity

Mar 3, 2022


Six top tips to prepare for the new EU Clinical Trial Regulation

Apr 13, 2021


In Conversation: Leadership Lessons on Diversity, Equity, & Inclusion, and the Future of Work

Apr 29, 2021


Importance of Diversity, Equity and Inclusion (DE&I) in medical communications

Jun 8, 2021


Tencent-Backed Wedoctor Is Going Public: What Are the Next Steps for Chinese Digital Health Companies?

Jun 30, 2021


Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021


India, the Generic Manufacturing Powerhouse, Biosimilar Next?

Jul 21, 2021


Evidence Generation Strategy under Germany’s Digital Healthcare: Is More Better?

Aug 6, 2021


Highlights from ISMPP Asia Pacific Meeting 2021

Sep 20, 2021


3 ways to incorporate DE&I in your communications strategy

Sep 29, 2021